About: OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.50 (+0.67%)
OKYO NASDAQ OKYO Pharma Limited
OKYO Pharma Limited share price
Atividade de preço de OKYO
Último preço
$ 1,500
Variação (24h)
0,01 USD (0,67%)
Volume
18.81K
Volume (média 4 sem.)
-
Abertura
$ 1,46
Variação do dia
$ 1,46 - $ 1,51
Fechamento anterior
$ 1,49
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
OKYO price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals